Protara Therapeutics (TARA) Curent Deferred Tax Liability (2013)

Protara Therapeutics' (TARA) quarterly Curent Deferred Tax Liability came in at $267000.0 in Q4 2013.

Protara Therapeutics (TARA) Curent Deferred Tax Liability (2013) Analysis & Trends

Protara Therapeutics (TARA) has 1 years of Curent Deferred Tax Liability data on file, last reported at $267000.0 in Q4 2013.

On a quarterly basis, Curent Deferred Tax Liability changed N/A year-over-year to $267000.0 in Q4 2013; TTM through Dec 2013 was $267000.0, a N/A change from a year earlier, with the FY2013 full-year figure at $267000.0, changed N/A from the prior year.
Curent Deferred Tax Liability for Q4 2013 stood at $267000.0.
Over the last five years, Curent Deferred Tax Liability for TARA reached as high as $267000.0 in Q4 2013 and fell as low as $267000.0 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Protara Therapeutics	2.25 Mn	2.25 Mn	-	-

Download Data

Date	Value
Dec 31, 2013	267,000.00
Dec 31, 2013	267,000.00